Q-omics provides the consensus-scored TBXA2R profile across patient tissues and cancer cell-line models. TBXA2R expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, TBXA2R is differentially expressed in 13, with the highest sampling consensus in HNSC. Additionally, TBXA2R protein abundance shows 17,803 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight MESO, HNSC, and GBM as cancer lineages where TBXA2R shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TBXA2R — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TBXA2R survival associations across molecular data types. TBXA2R RNA expression shows survival associations in the most cancer types (26), followed by mutation status (7) and mass-spec protein abundance (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TBXA2R RNA expression–survival associations across cancer types. High TBXA2R expression shows unfavorable associations in MESO, ACC, KIRP, LUSC and CESC, but favorable associations in KIRC. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for TBXA2R RNA expression.
This table summarizes TBXA2R tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 5. The strongest signals are observed in HNSC for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for TBXA2R. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TBXA2R shows lower tumor expression in KIRP, BLCA, LUSC and LIHC and higher tumor expression in HNSC and KIRC. The HNSC box plot shows higher TBXA2R RNA expression in tumor versus normal tissue (log2 FC = +1.393, t-test p < 0.001).
This table shows molecular features associated with TBXA2R in patient tissues and cancer cell lines. In patient samples, TBXA2R shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, TBXA2R RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and URINARY_TRACT.
